Posted inClinical Updates Wellness & Lifestyle
Safety and Efficacy of Rotigotine in Frontotemporal Dementia: Insights from a Phase 2 Double-Blind Multicenter Trial
This phase 2 trial found no significant cognitive or behavioral benefits of rotigotine in bvFTD patients over 24 weeks, highlighting the challenges in dopaminergic therapy for frontotemporal dementia.